On Wednesday, Brunswick Corporation (NYSE:BC)’s shares declined -0.02% to $47.79.
Brunswick Corporation (BC) declared an extension of its joint venture with Commercial Distribution Finance (GECDF), a division of GE Capital, through 2019. The joint venture, Brunswick Acceptance Company (BAC), was formed in 2002 and the current agreement was to expire at the end of 2016.
The programs offered by BAC are exclusive to dealers of Brunswick boat brands and Mercury Marine engines in the United States. Presently more than 600 dealers take part in the programs, often with multiple Brunswick brands in their dealerships.
Brunswick Corporation designs, manufactures, and markets recreation products in the United States and internationally. The company’s Marine Engine segment offers outboard engines, sterndrive propulsion systems, and inboard engines under the Mercury, Mercury MerCruiser, Mariner, Mercury Racing, Mercury Sport Jet and Mercury Jet Drive, MotorGuide, Axius, and Zeus brands; and marine electronics and control integration systems, steering systems, instruments, controls, propellers, trolling motors, fuel systems, service parts, and marine lubricants under the Quicksilver, Mercury Precision Parts, Mercury Propellers, Attwood, Land N Sea, Kellogg Marine Supply, Diversified Marine Products, Bell Recreational Products, Sea Choice, and MotorGuide brands, in addition to supplies integrated diesel propulsion systems. It serves independent boat builders and end users, in addition to local, state, and foreign governments through a network of marine dealers and distributors, specialty marine retailers, and marine service centers.
Hershey Co(NYSE:HSY)’s shares dropped -0.01% to $88.18.
The Hershey Company (HSY) declared the pricing of its offering of $300 million of 1.600% notes due 2018 and $300 million of 3.200% notes due 2025 (the “Notes Offering”) in a public offering. The Hershey Company intends to use the net proceeds of the Notes Offering to repay at maturity its $250 million aggregate principal amount of 4.85% Notes due 2015, to fund its cash tender offer for up to $100 million aggregate purchase price of its $100 million aggregate principal amount of 8.80% Debentures due 2021 and its $250 million aggregate principal amount of 7.20% Debentures due 2027 and for general corporate purposes.
A registration statement regarding the Notes Offering has been filed with the U.S. Securities and Exchange Commission and is effective. This press release shall not constitute an offer to sell or an offer to buy any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes Offering may be made only by means of a prospectus supplement and the accompanying prospectus.
The Hershey Company manufactures, imports, markets, distributes, and sells confectionery products. The company operates through two segments, North America; and International and Other. It offers chocolate and sugar confectionery products; pantry items, such as baking ingredients, toppings, sundae syrups, and beverages; snack items, counting spreads; and gum and mint refreshment products comprising chewing gums and bubble gums.
At the end of Wednesday’s trade, Fairchild Semiconductor Intl Inc (NASDAQ:FCS)‘s shares surged 5.06% to $13.30.
Fairchild (FCS), a leading global supplier of high-performance semiconductor solutions, recently launched its industry-leading mid-voltage MOSFET technology in a Dual Cool™ 8mm x 8mm package. The new Dual Cool 88 MOSFET gives power conversion engineers a first-of-its-kind alternative to bulky D2-PAK packages at half the size and with higher power density, superior efficiency and better cooling via air flow above and beneath the package.
Fairchild Semiconductor International, Inc. designs, develops, manufactures, and markets power analog, power discrete, and non-power semiconductor solutions worldwide. It operates through three segments: Mobile, Computing, Consumer, and Communication (MCCC); Power Conversion, Industrial, and Automotive (PCIA); and Standard Discrete and Standard Linear (SDT). The MCCC segment offers analog components, mixed signal integrated circuits (ICs), and low voltage power metal oxide semiconductor field effect transistors (MOSFETs) for mobile, consumer, computing, and communication applications; signal path products, such as analog and digital switches, USB switches, video filters, and audio amplifiers; and packaging solutions comprise surface mount devices, tiny packages, chip scale packages, and leadless carriers. Its analog products monitor, interpret, and control variable functions comprising light, color, sound, and energy. The PCIA segment provides analog and mixed signal ICs, multi-chip smart power modules, and discrete power products. Its analog and mixed signal ICs are used to control discrete semiconductors in applications, counting power switching, conditioning, signal amplification, power distribution, and power consumption. The SDT segment offers a range of semiconductor products, such as MOSFET, junction field effect transistors, high power bipolar, discrete small signal transistors, Zener diodes, rectifiers, bridge rectifiers, Schottky devices, and diodes; bipolar regulators, shunt regulators, low drop out regulators, standard op-amp/comparators, low voltage op-amps, and others; and infrared products.
Acorda Therapeutics Inc (NASDAQ:ACOR), ended its Wednesday’s trading session with 1.82% gains, and closed at $31.96.
Acorda Therapeutics Inc (ACOR) declared that it has put a hold on a Phase 1b clinical trial of cimaglermin alfa based on the occurrence of a case of hepatotoxicity (liver injury) meeting Hy’s Law criteria (elevated ALT, AST and bilirubin).
There was also one case of hepatotoxicity meeting Hy’s Law criteria stated in the previous Phase 1 clinical trial of cimaglermin, which resolved within several days. The Company has ongoing non-clinical studies to investigate the pathological basis for liver interactions.
The Company plans to review these and other data from the cimaglermin trials with the U.S. Food and Drug Administration (FDA). Following talk about with the FDA, the Company will provide an update on the cimaglermin program.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the administration of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the administration of neuropathic pain associated with post-herpetic neuralgia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
